Phythera Therapeutics converts nature-derived anti-cancer compounds from medicinal plants into prescription oncology drugs. The company leverages advancements like liposomal delivery and AI-driven design to enhance the bioavailability and efficacy of these botanical extracts. This approach aims to create safer, multi-target cancer treatments utilizing the FDA's botanical drug regulatory path.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often have limitations in efficacy and can cause harmful side effects, impacting the quality of life for patients, especially those with metastatic cancer. Traditional drug development processes for combination therapies are complex and expensive, particularly when dealing with multiple active components.
Solution
Phythera Therapeutics is developing enhanced botanical-derived oncology drugs, leveraging the FDA's Botanical Drug Development Guidance to create safer and more effective treatments. The company's approach involves improving upon naturally occurring anti-cancer compounds found in plants, using advanced techniques such as liposomal drug delivery, small molecule conjugation, and AI-driven small molecule design. These methods enhance bioavailability, stability, safety, and tissue penetration, while also increasing the affinity of the drugs to their targets. Phythera's lead drug candidate, MetPhyte(TM) Plus, is derived from a plant with known anti-cancer properties and is being developed as a prescription drug for oncology.
Target Audience
Phythera Therapeutics is focused on providing enhanced botanical-derived drug formulations to oncology patients, particularly those with metastatic cancer, seeking treatments with improved efficacy and reduced side effects.
Features
- Enhanced botanical drug formulations based on plant-derived anti-cancer compounds.
- Utilizes liposomal drug delivery to improve drug bioavailability and targeted delivery.
- Employs small molecule conjugation to enhance drug stability and efficacy.
- Leverages AI-driven small molecule design for improved drug properties.
- Developing MetPhyte(TM) Plus, a patented composition, as a lead drug candidate.
- Following the FDA's Botanical Drug Development Guidance for regulatory approval.